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This issue marks the 20th year since the launching of RNA in
March of 1995. It is a time to celebrate, as well as to consider
the substantial accomplishments achieved in these two de-
cades, both in the RNA field as a whole, and in the specific
areas in which each of us works—in my case, human pre-
mRNA splicing mechanisms and regulation, and its relevance
to human disease. Moreover, this is a time to reflect about
where our field is headed, and what are the unique opportu-
nities and obstacles in our path.
With no intention of being exhaustive in listing major
achievements, I would first single out certain technical ad-
vances from which virtually everyone in the RNA field and
beyond is substantially benefitting, and which satisfyingly
emerged from careful characterization of novel natural phe-
nomena. One of these is RNA interference, which has led to
various powerful, widely used tools for targeted gene knock-
down, as well as tomajor efforts in therapeutics development.
A more recent example consists of the prokaryotic CRISPR/
Cas systems, which are rapidly being adapted as powerful
tools for targeted genome editing.
Other important technical developments include methods
for massively parallel RNA-sequence analysis, and related
techniques for systematically footprinting binding sites of
proteins or RNP complexes on RNA (e.g., ribosome profil-
ing, CLIP). These methods take advantage of the availability
of complete or nearly complete genome sequences, and re-
quire appropriate use of computational and statistical tools.
Advances in the field of pre-mRNA splicing have contin-
ued steadily, and resulted in a comprehensive inventory of
small RNAs and proteins involved in the various stages of
spliceosome assembly, transesterification catalysis, and re-
lease of mature mRNA. Important insights have emerged
concerning the interplay between splicing and other steps
in mRNA biogenesis, including transcription and the various
relevant features of chromatin, processing at the 5′ and 3′
ends, mRNA export and localization, and mRNA turnover.
New complexes have been identified, notably the nuclear
exosome and the exon-junction complex, with functionally
important roles in RNA turnover and quality control.
Structure determination continues to provide crucial in-
sights, and the splicing field awaits a breakthrough compara-
ble to the high-resolution structures of ribosomes, which led
to a renaissance in the field of translation. However, the
dynamic nature of the spliceosomemakes this especially chal-
lenging. In the meantime, many detailed structures of subas-
semblies and individual components of the spliceosome, or
fragments thereof, have been obtained, allowing steady pro-
gress in elucidating structure-function relationships. Promi-
nent examples include structures of the U1 snRNP and of a
large fragment of PRP8.
The discovery and characterization of the minor spliceo-
some, which processes so-called U12-dependent introns,
began after the inception of RNA (though its existence was
predicted slightly earlier). Although only a tiny proportion
of genes possess U12-dependent introns, the origin and evo-
lution of parallel spliceosome pathways are very intriguing,
comparisons with the major pathway have yielded insights
for both pathways, and certain mutations in minor introns
or in components of the minor spliceosome are disease-caus-
ing. Thus, this is a splicing pathway that deserves continued
attention.
Characterization of the basic mechanisms and regulation
of pre-mRNA splicing has enabled important advances in un-
derstanding the pathogenesis of various diseases, including
genetic diseases, cancer, and infectious diseases, as well as cre-
ated opportunities for therapeutics development. At the level
of single-gene lesions, our understanding of which mutations
cause missplicing has been augmented by insights into splic-
ing-regulatory elements (enhancers and silencers), minor and
non-canonical splice-site consensus sequences, and alterna-
tive base-pairing registers with snRNAs. Mutations in splic-
eosome components can also cause disease; for example,
specific recurrent mutations in particular sets of components
give rise tomyelodysplastic syndrome and retinitis pigmento-
sa. In addition, sequestration of a regulatory splicing factor,
MBNL, by an RNA-repeat expansion gives rise to myotonic
dystrophy, and reduced levels of a snRNP-assembly factor,
SMN, results in spinal muscular atrophy.
Mechanistic knowledge has enabled the development of
targeted therapeutics that are now being tested in the clinic.
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For example, antisense/RNaseH-mediated cleavage is being
used to destroy the DMPK mRNA that sequesters MBNL
(myotonic dystrophy), and splicing modulation by an anti-
sense oligonucleotide or by a small molecule is being used
to restore correct SMN2 pre-mRNA splicing and thereby in-
crease the levels of SMN (spinal muscular atrophy). In addi-
tion, forcing exon skipping by antisense blocking of splice
sites or splicing enhancers is being used to restore the correct
translational reading frame in the context ofDMDmutations
in Duchenne muscular dystrophy, or to trigger nonsense-
mediated mRNA decay and reduce gene expression.
Much work remains to be done to fully understand the
logic of splicing, from the mechanistic details of how an in-
dividual intron is removed through the coordinated action
of five snRNAs and hundreds of polypeptides, to the process-
ing of numerous introns of widely different sizes from sin-
gle pre-mRNAs, the high-fidelity recognition of >200,000
pairs of splice sites with substantial sequence variation, and
the regulated choice of alternative splice sites in different
contexts, as guided in part by the combinatorial effects of
many splicing activators and repressors recognizing a diverse
set of exonic and intronic enhancers and silencers. Such
detailed knowledge will be essential to correctly interpret
the information encoded in our genome, and to gain fur-
ther insights into disease mechanisms. Multidisciplinary
approaches, including various experimental and computa-
tional methods, are indispensable to effectively tackle these
questions.
Studies involving RNA-seq yield massive datasets, whose
analysis requires appropriate bioinformatic and statistical ex-
pertise. Interrogating the entire transcriptome can be ex-
tremely informative, and not surprisingly, this type of
approach is becoming commonplace. However, in my opin-
ion, rigorous standards have yet to be implemented for au-
thors, referees, editors, and readers to be able to effectively
present, evaluate, and understand this type of data. In addi-
tion, published high-throughput data generated for a specific
purpose can be subsequently mined to address different
questions, as long as these data meet appropriate standards
for collection and reporting.
In the last 20 years, there have been substantial changes in
how scientific findings are published. Increasingly, this is a
source of much frustration for scientists. Many journals arbi-
trarily limit the length of theMethods section and the number
of references allowed, even though these are crucial for others
to be able to reproduce the findings and for scholarly presen-
tation. Important details have to be relegated to an online sup-
plement that often is not rigorously reviewed or edited, and
whichmay not remain accessible indefinitely. Arbitrary edito-
rial rejections, destructive reviews, deliberate delays, and un-
warranted requests for additional experiments—without
consideration of cost or time—have become unacceptably
common. Regrettably, these trends slow down the progress
of science and waste valuable resources. Yet, the strong pres-
sure to publish in high-profile journals—associated with
competition for limited research funds and with career ad-
vancement—exacerbates the problem.
Fortunately, RNA is one of a few quality journals that pro-
tect us from these destructive trends. The editors are active
scientists with recognized expertise in their respective areas,
and personal knowledge of researchers in the field, which
greatly helps to keep the review process honest and efficient,
and to prevent or manage potential conflicts. We should be
grateful for their selfless dedication, which has made possible
the first 20 years of RNA’s informative publications on all as-
pects of RNA science.
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